Literature DB >> 8188696

Inhibition of type-1 plasminogen activator inhibitor production by antisense oligonucleotides in human vascular endothelial and smooth muscle cells.

H Sawa1, B E Sobel, S Fujii.   

Abstract

We have hypothesized that type-1 plasminogen activator inhibitor (PAI-1) may exacerbate accumulation of extracellular matrix in atheroma by inhibiting local generation of plasmin and intramural proteolysis. Thus, suppression of PAI-1 expression would decrease atherogenesis. To inhibit expression of PAI-1 in cultured human umbilical vein endothelial and aortic smooth muscle cells, a 20-base antisense phosphorothioate oligonucleotide targeting specific sequences in the 3'-untranslated region of the PAI-1 gene was used. Studies with 32P-labeled oligomers verified stability in media. Secretion of PAI-1 protein assayed by enzyme-linked immunosorbent assay declined specifically and dose-dependently in cells exposed to the antisense oligonucleotide treated under basal conditions and after stimulation of PAI-1 expression with transforming growth factor beta (0.5 ng/ml for endothelial cell, 5 ng/ml for smooth muscle cell). Inhibition of expression was confirmed by immunoprecipitation of 35S-labeled PAI-1 and was paralleled by decreased steady-state levels of PAI-1 mRNA (Northern blots). Decreased PAI-1 synthesis was accompanied by augmentation of cell-associated plasmin activity. Thus, the antisense oligonucleotide down-regulated PAI-1 elaboration, an approach that may be useful in limiting obstructive vascular lesions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8188696

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  3 in total

1.  Plasminogen activator inhibitor-1 antisense oligodeoxynucleotides abrogate mesangial fibronectin accumulation.

Authors:  Jehyun Park; Ji Yeon Seo; Hunjoo Ha
Journal:  Korean J Physiol Pharmacol       Date:  2010-12-31       Impact factor: 2.016

2.  Plasminogen Activator Inhibitor 1: Molecular Aspects and Clinical Importance.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

3.  Dependence of Human Vascular Cell Surface Proteolysis on Expression of the Urokinase Receptor.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.